LDH-1 Test

When cells are injured or dying, they leak their contents into the bloodstream. One of the proteins that spills out is lactate dehydrogenase, an enzyme involved in how every cell converts sugar into energy. Your body makes five different versions of this enzyme, each concentrated in different organs. LDH-1 (lactate dehydrogenase isoenzyme 1) is the version packed most densely into heart muscle cells and red blood cells. When your LDH-1 is elevated, the damage trail almost always leads back to one of those two sources.

For decades, LDH-1 was one of the primary tools doctors used to confirm a heart attack. Newer cardiac markers have taken over that role, but LDH-1 still provides unique information that total LDH alone cannot: it tells you which tissue is breaking down. If you already know your total LDH is high, this test helps answer the question that matters most: where is the damage coming from?

How LDH-1 Fits Into the Family

Your body produces five LDH isoenzymes, numbered 1 through 5. Each is built from a different combination of two protein building blocks: an H (heart) subunit and an M (muscle) subunit. LDH-1 is made entirely of four H subunits, which is why it concentrates in heart tissue and red blood cells. LDH-5, at the other end of the spectrum, is four M subunits and concentrates in the liver and skeletal muscle.

In healthy blood, LDH-2 is usually the most abundant isoenzyme, followed closely by LDH-1. When LDH-1 rises above LDH-2, doctors call this a "flipped" ratio, and it signals significant damage to heart cells or destruction of red blood cells.

Heart Attack Diagnosis: The Historical Role

LDH-1 earned its clinical reputation as a heart attack detector. After a heart attack, damaged heart muscle cells release their LDH-1 into the blood. In a study of 100 patients with suspected heart attacks, checking whether LDH-1 had "flipped" above LDH-2 correctly identified heart attacks 96% of the time and correctly ruled them out 97% of the time. A separate study of 478 patients found that the same flipped ratio caught 100% of confirmed heart attacks, with 90.5% accuracy in correctly ruling out those who had not had one.

The LDH-1 signal was especially useful in a specific window. Another study of 65 patients showed that the LDH-1 to total LDH ratio became abnormal within the first day of hospitalization, with a 96% predictive value. In patients undergoing heart surgery, measuring LDH-1 between 24 and 42 hours after the operation proved useful for catching heart damage that occurred during surgery. One analysis found that the ratio of LDH-1 to total LDH was more accurate than CK-MB (creatine kinase MB, another heart damage marker) for confirming small or evolving heart attacks where CK-MB results were borderline.

How LDH-1 Compares to Troponin

If LDH-1 was so accurate, why did it get replaced? The answer is speed and specificity. Cardiac troponin (a protein released from damaged heart muscle) can be detected sooner after a heart attack, stays elevated longer, and is more specific to heart tissue. A comparison study found that cardiac troponin I was at least as sensitive as LDH isoenzymes for confirming heart attacks, and another study of 36 patients showed troponin had greater sensitivity for catching heart damage that presented late, days after the event.

This does not mean LDH-1 is obsolete. Troponin is now the first choice for acute heart attack diagnosis, but LDH-1 still adds value in specific situations: when you need to distinguish heart damage from red blood cell destruction, when you are monitoring tissue injury over time in conditions like sickle cell disease, or when total LDH is high and the clinical picture is unclear.

Red Blood Cell Destruction and Sickle Cell Disease

Because LDH-1 is highly concentrated in red blood cells, it rises sharply when red blood cells are being destroyed faster than normal, a process called hemolysis. In a study of 213 patients with sickle cell disease, the LDH-1 to LDH-2 pattern reflected an entire syndrome of complications. Patients with higher LDH (driven by the LDH-1 fraction from red blood cell destruction) were more likely to develop pulmonary hypertension (high blood pressure in the lungs), leg ulcers, and priapism (a painful, prolonged erection). These complications were linked to a chain reaction: destroyed red blood cells release hemoglobin, which depletes nitric oxide (a molecule that keeps blood vessels relaxed), leading to blood vessel dysfunction and organ damage.

If you have sickle cell disease or another hemolytic condition, a disproportionately high LDH-1 relative to LDH-2 tells you that red blood cell destruction is a major driver of your total LDH elevation, not liver damage or something else. That distinction matters because the treatment approach differs depending on the source.

Cancer Monitoring

In a study of 127 patients with various cancers, researchers found an abnormal LDH-1 related band (called "LDH-1 ex") that appeared in the blood of many patients with active malignancies. The presence of this band was strongly linked to cancer, and it disappeared after successful treatment with chemotherapy, radiation, or surgery. This suggests LDH-1 patterns can serve as a way to track whether cancer treatment is working.

In at least one documented case, a patient with a germ cell tumor in the chest showed unusually high LDH-1 due to changes in how the tumor's genes were regulated, specifically through a chemical modification of the gene that normally produces the M subunit. This kind of finding shows that some tumors can shift the balance of LDH isoenzymes in distinctive ways.

Total LDH (all five isoenzymes combined, which is a related but different measurement than LDH-1 alone) has been extensively studied as a cancer prognosis marker. Multiple meta-analyses show that elevated total serum LDH predicts worse survival in lung cancer, prostate cancer, liver cancer, renal cell carcinoma, bladder cancer, and melanoma. In a retrospective study of 4,337 cancer patients, higher total LDH was associated with increased mortality risk, with optimal ranges identified for both sexes. These findings apply to total LDH, not to LDH-1 specifically, but they provide context for why doctors pay attention when any LDH measurement is elevated in a cancer patient.

Total LDH and Broader Disease Associations

Total serum LDH (not broken down by isoenzyme) has been linked to outcomes across a wide range of serious illnesses. These findings are about total LDH rather than LDH-1 specifically, but they are relevant context for anyone interpreting an LDH isoenzyme panel.

In a massive analysis of over 182,000 patients, elevated total LDH was found in 46 out of 48 disease categories studied. A pooled analysis of COVID-19 patients found that elevated LDH at hospital admission was associated with about a 6-fold increased risk of developing severe disease and roughly a 16-fold increased risk of dying. In a study of 685 elderly patients with heart attacks, high baseline LDH predicted future cardiac dysfunction during follow-up. And in an analysis of 8,179 patients with heart failure and reduced pumping ability, higher LDH levels were independently associated with worse outcomes including death and hospitalization.

The pattern is consistent: when total LDH is high, cells are being damaged somewhere in the body, and the more damage there is, the worse the outlook tends to be. LDH-1 helps you narrow down where that damage is happening.

Reference Ranges and Diagnostic Cutoffs

LDH-1 does not have a single universal "normal" range the way cholesterol or blood sugar does. Values depend on the lab method used, and results are most meaningful when interpreted as a ratio (LDH-1 relative to LDH-2 or to total LDH) rather than as a standalone number. The following cutoffs come from specific clinical studies and should be treated as orientation, not universal targets. Your lab may report different units or ranges.

In healthy people, LDH-1 typically accounts for roughly 17% to 27% of total LDH, and LDH-2 is slightly higher. The moment LDH-1 overtakes LDH-2, something is wrong with your heart cells or your red blood cells. Compare your results within the same lab over time for the most meaningful trend.

When Results Can Be Misleading

The biggest confounder for LDH-1 interpretation is hemolysis during sample collection. If red blood cells are broken during the blood draw itself (from a difficult stick, shaking the tube too hard, or leaving a tourniquet on too long), LDH-1 will be falsely elevated. One study confirmed that even modest hemolysis in the sample can increase the LDH-1/LDH-2 ratio enough to mimic a heart attack pattern. If your LDH-1 is unexpectedly high and you had a rough blood draw, ask for a repeat test with careful sample handling.

Intense exercise within 24 to 48 hours before testing can temporarily elevate total LDH, potentially affecting the isoenzyme distribution. Acute illness, surgery, and significant physical trauma can all raise LDH across multiple isoenzymes, making it harder to interpret the LDH-1 fraction in isolation. For the most reliable reading, draw blood when you are in a stable baseline state, not within a day or two of heavy exercise, surgery, or acute illness.

Tracking Your Trend

A single LDH-1 measurement is a snapshot. Its real power emerges when you track it over time. In the cancer monitoring study, the abnormal LDH-1 band disappeared after successful treatment and reappeared with disease recurrence. Serial measurements allowed doctors to detect relapse before other signs appeared. In sickle cell disease, trending LDH over time helps gauge whether hemolysis is worsening or stabilizing.

If you are using LDH-1 to monitor a known condition, your doctor will likely set a testing schedule based on your treatment cycle. If you are checking it as part of a broader investigation into elevated total LDH, start with a baseline measurement, confirm any abnormality with a repeat test two to four weeks later (ruling out sample hemolysis or transient illness), and then retest at intervals that make sense for your clinical situation, typically every three to six months if actively monitoring a condition.

What to Do With Your Results

If your LDH-1 is elevated or the LDH-1/LDH-2 ratio is flipped, the next step depends on context. If you have no known cardiac or hematologic condition, the first move is to rule out a sample handling problem by retesting. If the elevation persists, the decision tree branches based on your symptoms and other labs.

• If you have chest pain or cardiac symptoms: High-sensitivity troponin is the definitive next test. LDH-1 provides supporting evidence but troponin is the current standard for confirming heart damage. A cardiologist should be involved.
• If you have signs of anemia or hemolysis (fatigue, pallor, dark urine, jaundice): A complete blood count with reticulocyte count (a measure of how many young red blood cells your bone marrow is producing), haptoglobin (a protein that drops when red blood cells are being destroyed), and indirect bilirubin will help confirm whether red blood cells are being destroyed and guide you toward a hematologist.
• If you are monitoring cancer treatment: Compare LDH-1 to your pre-treatment baseline. A rising LDH-1 pattern during or after treatment warrants discussion with your oncologist about disease activity.
• If total LDH is high but you feel fine: LDH isoenzyme fractionation (this test) helps identify the source tissue. If LDH-1 is not the dominant fraction, the elevation may be coming from liver (LDH-5) or lung (LDH-3) instead.

LDH-1 works best as part of a clinical puzzle, not as a standalone verdict. Pair it with the right companion tests, and it can point you toward the organ or cell type that needs attention.